-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $61

Benzinga·11/11/2026 15:22:59
Listen to the news
Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $68 to $61.